10,000 publications from this institution
Mounting research supports that co-rumination, the tendency to seek peer support by engaging in extensive negatively focused discussion, is a risk factor for adolescent psychopathology. It is unclear, though, how this interpersonal tendency develops. Parental responses to adolescents’ negative affect likely shape how youth utilize peer relationships to regulate distress, as they shift to reliance on peer support during this developmental stage. For example, nonsupportive parental responses may fail to instill healthy regulation strategies, resulting in ineffective forms of peer support, such as co-rumination. Conversely, high levels of supportive parental responses to adolescents’ negative affect may motivate youth to also express more negative affect with peers, leading to co-rumination. Eighty-nine healthy adolescents (9-17) and their mothers completed surveys and a support-seeking interaction. Only supportive maternal responses, including maternal affection, were associated with adolescents’ co-rumination. These analyses indicate that some forms of parental support are associated with adolescents’ tendency to co-ruminate.
Silicon photonics is a rapidly maturing platform for optical communication and sensing. As systems leveraging silicon photonics have grown in size and complexity, so too has the demand for high performance silicon photonics components. In order to meet these demands, inverse electromagnetic design has gained attention as a general tool for optimizing sophisticate silicon photonic devices. In this talk, we demonstrate how inverse electromagnetic design methods can be systematically applied to design high performance devices which both satisfy practical fabrication constraints and which are insensitive to manufacturing variations. These results pave the way for high efficiency silicon photonic component libraries.
The Covid-19 pandemic will have major implications for public trust in scientific expertise. But will this effect be positive or negative, and will it affect trust in individual scientists or science more broadly? Cevat Giray Aksoy, Barry Eichengreen and Orkun Saka write that people aged 18 to 25, whose core beliefs are still being formed, are likely to suffer the strongest impact of Covid-19 on their faith in scientists, but not in science.
Abstract Here, we report on a Si–air/ionic liquid electrolyte battery whose performance improves with small amounts of water in the electrolyte. The shift of the generation zone of the SiO 2 discharge product from the air cathode surface into the bulk region of the liquid electrolyte, caused by water addition, is demonstrated through various means. Addition of 15 vol % water leads to an increase of 40 % in the discharge capacity as compared to the capacity obtained using a pure ionic liquid electrolyte. If the water content increases above 20 vol %, the Si–air cell capacity dramatically decreases. The water–ionic liquid electrolyte mixture shows a maximum in the ionic conductivity with a water content of 10 vol %. In‐depth studies indicate a reduced amount of discharge product at the air electrode using 15 vol % H 2 O electrolyte. The morphology of the anode surface, as well as the developed surface film in the presence of water‐containing ionic liquid, is reported. This study shows that exposing a Si–air battery to a humid environment does not result in capacity losses, but rather improves cell performance.
A low-copy expression vector has been constructed from a 9 Kbp region of the Escherichia coli F plasmid containing the oriV and oriS origins of replication. This plasmid carries the β-lactamase gene (Apr) and the araBAD promoter/araC regulator for arabinose-inducible gene expression. A derivative which carries a lacZ reporter gene was found to be stably maintained for at least 150 generations. A related multi-copy plasmid was stably maintained in arabinose-free medium, but no plasmid-bearing segregants remained after 60 generations when lacZ expression was induced. Induced expression resulted in 27% (multi-copy) and 12% (low-copy) decreases in growth rate. The uninduced levels of β-galactosidase were 200 units (multi-copy) and 15 units (low-copy). © 1998 John-Wiley & Sons, Inc. Biotechnol Bioeng 59:659–665, 1998.
I'M GOING TO TALK about plug-and-play biology. And I'm g oing to first introduce it by talking about a problem, a problem many of you may know about. It's malaria. It actually affects about Ia quarter of the world's population; 2.4 billion people are at risk of getting malaria at any one time; between 300 and 500 million people have the disease, and every year between one and three million people die of the disease. Ninety percent are children under the age of five.And of those countries most affected by malaria, economists have noted that it reduces their GDP by roughly half. So it's a hugely debilitating disease. The drugs that are currently available are based largely on quinine. Quinine has been around for four hundred years; wars were fought for access to quinine. And it's been so widely used and abused that Plasmodium, which causes malaria, has grown resistant to it. So, widely available, inexpensive, and no longer effective.This is artemisinin (fig. 1). It comes from this plant Artemisia annua and it's a miracle cure, really, for malaria. It's been around for literally centuries. It was discovered in about 168 BC by the Chinese. There are some writings about its use, first for treating hemorrhoids and later for treating fevers. It was largely forgotten until the 1960s, when the Chinese were fighting in Vietnam and they needed a cure for the severe malaria there. They went back to their literature; they purified the active ingredient, and the rest is history.Now, here's how we get artemisinin. It's actually produced by this plant Artemisia annua in sacs called trichomes on the surface of the leaves. So there are basal cells in these trichomes and they push this oil, this artemisinin, up into these bags, and when you rub the leaf, you actually get it off.Now we get artemisinin from farmers who grow plants. There are a lot of plantations, primarily in Southeast Asia, where they grow the plant. They then purify it, from the plant; they purify it using the only solvent they have available-gasoline. There's a big problem. A few years ago when they were using leaded gasoline, the lead was contaminating the artemisinin supply, and then that's sold to the farmer for conversion into the various derivatives that are currently in use for treating malaria. Artesanate looks like it's going to be the best derivative of artemisinin because it's water soluble and it can be formulated in IVs.In 2005 the World Health Organization recommended artemisinin combination therapies as the drug of choice for treating malaria. These bars here (fig. 2) show artemisinin combination therapies delivered over that period. You can see there's a huge ramp-up primarily around 2006 and 2007. It takes about eighteen months to two years to get seeds in the field and artemisinin delivered to the farmers, so you need a very long lag time.Now here's where we project the demand will go. This is largely due to the Gates Foundation, the Clinton Global Fund, and the World Bank's making these drugs available. So there's going to be a huge demand for them. We're going to need on the order of 300 million treatments every year for malaria.Now when artemisinin was recommended as the drug of choice for treating malaria in 2005, the price spiked. This is one of the severe problems with artemisinin: the price fluctuates while there is an open market.So the price spiked and farmers started planting it like crazy, and that is shown right here (fig. 3). By 2007 there was a huge over-supply of artemisinin. What happened? They stopped planting it. The price of food went up, and they are no longer planting artemisinin. You can see that the prices are sitting down here because we have this over-supply, but the problem is that we're living on that over-supply from 2007.And guess what? Next year that supply runs out. And in fact we have a deficit. And if you look forward, there's going to be a huge u nder-supply by about 250 million treatments, which means the prices are going to go back up. …